BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sosei Group Corporation Announces Buyback of the Commercialization Rights to AD 923 from Mundipharma AG


12/29/2008 6:59:33 AM

TOKYO, Dec. 26 /CNW/ - Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has re-acquired the rights for commercialization of AD 923 from Mundipharma International Corporation Ltd. ("Mundipharma").

AD 923 is an optimized, sublingual formulation of the strong opioid analgesic fentanyl for the treatment of cancer breakthrough pain. It has been specifically designed to provide rapid onset of analgesia in a device that is easy to use by either the patient or their care giver. An additional benefit is the lockout system that prevents inadvertent overdosing.

In June 2006, Sosei entered into a licence agreement with Mundipharma, under which Mundipharma were granted the right to commercialize AD 923 in Europe and other international markets, excluding North America and Japan.

In February 2008, the programme entered Phase III clinical trials in Europe. However, due to a problem concerning a supplied component in the device used to deliver the fentanyl spray, the trial was temporarily halted in March 2008.

A solution to the technical problem with the device has since been identified, but Sosei is no longer in a position financially to continue with the programme and a new partner is being sought to progress clinical development.

The buyback of the Mundipharma rights now provides Sosei with the possibility of offering commercialisation rights on a global basis. The Mundipharma rights will be re-acquired for a mutually agreed sum of pounds sterling 2m, plus an additional 20% (up to a maximum of pounds 1.5m) of net receipts if Sosei enters into a new partnership agreement involving the Mundipharma territory.

Sosei Group Corporation Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan Hiroki MAEKAWA, Representative Executive Officer, E-mail: hmaekawa(at)sosei.com Tel: +81 3 5210 3399 Fax: +81 3 5210 3291

1F London BioScience Innovation Centre 2 Royal College Street, London NW1 0NH Non OSAKABE, PA to CEO E-mail: nosakabe(at)sosei.com Tel: +44-20-7691-2081 Fax: +44-20-7209-2484

Notes for Editors: About Sosei Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model based primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

For further information

Web Site: http://www.sosei.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES